Zydus And Alkem Receive Upgraded Valuations From HSBC Analysts

Market Momentum In Pharma

Global brokerage HSBC has revised upward its price targets for two major Indian pharmaceutical companies, Zydus Lifesciences and Alkem Laboratories. The move highlights optimism around the sector’s resilience and growth trajectory amid evolving healthcare demand.

Zydus Lifesciences Outlook

HSBC increased Zydus Lifesciences’ target price to 940 rupees from 915 rupees. The revision underscores expectations of steady revenue growth, driven by strong domestic formulations and expanding global generics presence.

Alkem Laboratories Outlook

Alkem Laboratories saw its target price raised to 5700 rupees from 5315 rupees. The upgrade reflects confidence in Alkem’s diversified portfolio, robust R&D pipeline, and consistent performance in both domestic and international markets.

Key Highlights

• HSBC raises Zydus target to 940 rupees
• HSBC raises Alkem target to 5700 rupees
• Signals confidence in Indian pharma sector growth
• Focus on domestic formulations and global generics
• Strong R&D pipeline supports long-term outlook

Sources: Market news reports, HSBC research updates